KZIA
Income statement / Annual
Last year (2025), Kazia Therapeutics Limited's total revenue was $42.00 K,
a decrease of 98.18% from the previous year.
In 2025, Kazia Therapeutics Limited's net income was -$20.70 M.
See Kazia Therapeutics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$42.00 K |
$2.31 M |
$555.00 |
$10.00 K |
$15.18 M |
$988.11 K |
$1.57 K |
$13.11 K |
$8.79 M |
$4.07 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$42.00 K
|
$2.31 M
|
$555.00
|
$10.00 K
|
$15.18 M
|
$988.11 K
|
$1.57 K
|
$13.11 K
|
$8.79 M
|
$4.07 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$7.33 M
|
$17.38 M
|
$15.56 M
|
$20.17 M
|
$14.54 M
|
$9.49 M
|
$6.48 M
|
$9.77 M
|
$11.14 M
|
$9.89 M
|
| General & Administrative Expenses |
$8.72 M
|
$13.56 M
|
$8.58 M
|
$5.11 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$127.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.72 M
|
$13.56 M
|
$8.58 M
|
$5.24 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
| Other Expenses |
-$1.79 M
|
-$173.00 K
|
-$22.56 K
|
$0.00
|
-$2.00 K
|
$0.00
|
-$9.00 K
|
$3.67 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.26 M
|
$30.77 M
|
$24.12 M
|
$25.41 M
|
$21.56 M
|
$13.18 M
|
$10.25 M
|
$14.69 M
|
$19.66 M
|
$15.64 M
|
| Cost And Expenses |
$14.26 M
|
$30.77 M
|
$24.12 M
|
$25.41 M
|
$21.56 M
|
$13.18 M
|
$10.25 M
|
$14.69 M
|
$19.66 M
|
$15.64 M
|
| Interest Income |
$72.00 K
|
$12.00 K
|
$22.84 K
|
$2.09 K
|
$42.24 K
|
$66.00 K
|
$100.00 K
|
$119.00 K
|
$276.00
|
$406.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$2.09 K
|
$0.00
|
$0.00
|
$2.19 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$934.00 K
|
$1.87 M
|
$1.87 M
|
$1.87 M
|
$1.27 M
|
$1.08 M
|
$1.08 M
|
$1.55 M
|
$1.41 M
|
$642.64 K
|
| EBITDA |
-$13.28 M |
-$26.59 M |
-$22.28 M |
-$23.52 M |
-$5.11 M |
-$11.11 M |
-$7.71 M |
-$10.82 M |
-$9.44 M |
-$11.72 M |
| EBITDA Ratio |
-316.26
|
-11.52
|
-40138.86
|
-2351.5
|
-0.34
|
-11.24
|
-4927.16
|
-825.07
|
-1.07
|
-2.88
|
| Operating Income Ratio |
-338.5
|
-12.33
|
-43466.61
|
-2539.9
|
-0.42
|
-12.34
|
-5354.63
|
-952.62
|
-1.23
|
-3.14
|
| Total Other Income/Expenses Net |
-$8.23 M
|
$1.41 M
|
$3.41 M
|
$17.00 K
|
-$2.53 M
|
-$569.58 K
|
-$1.75 M
|
$6.02 M
|
$7.87 K
|
$227.97 K
|
| Income Before Tax |
-$22.45 M
|
-$27.05 M
|
-$20.74 M
|
-$25.38 M
|
-$8.90 M
|
-$12.77 M
|
-$10.57 M
|
-$6.34 M
|
-$10.87 M
|
-$12.16 M
|
| Income Before Tax Ratio |
-534.48
|
-11.72
|
-37362.65
|
-2538.2
|
-0.59
|
-12.92
|
-6752.72
|
-483.98
|
-1.24
|
-2.99
|
| Income Tax Expense |
-$1.75 M
|
-$271.00 K
|
-$271.09 K
|
-$368.00 K
|
-$484.00 K
|
-$298.20 K
|
-$298.00 K
|
-$305.00 K
|
-$198.54 K
|
$2.77 M
|
| Net Income |
-$20.70 M
|
-$26.78 M
|
-$20.47 M
|
-$25.01 M
|
-$8.42 M
|
-$12.47 M
|
-$10.27 M
|
-$6.04 M
|
-$10.67 M
|
-$12.06 M
|
| Net Income Ratio |
-492.9
|
-11.6
|
-36874.2
|
-2501.4
|
-0.55
|
-12.62
|
-6562.3
|
-460.71
|
-1.21
|
-2.96
|
| EPS |
-18.9 |
-55 |
-55 |
-95 |
-35.8 |
-80 |
-85.6 |
-59.8 |
-109.3 |
-135.2 |
| EPS Diluted |
-18.9 |
-55 |
-55 |
-95 |
-35.8 |
-80 |
-85.6 |
-59.8 |
-109.3 |
-135.2 |
| Weighted Average Shares Out |
$1.10 M
|
$479.60 K
|
$368.60 K
|
$265.00 K
|
$235.40 K
|
$152.46 K
|
$120.01 K
|
$100.96 K
|
$97.63 K
|
$89.20 K
|
| Weighted Average Shares Out Diluted |
$1.10 M
|
$479.60 K
|
$368.60 K
|
$265.00 K
|
$235.40 K
|
$152.46 K
|
$120.01 K
|
$100.96 K
|
$97.63 K
|
$89.20 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
